Big picture - Why invest in Silence Therapeutics plc
Silence Therapeutics plc Snapshot
Our mission is to use our technology to create a new generation of therapeutics which can improve results for patients and, in the process, build shareholder value.
Silence’s strategy is based on translating our intellectual property, our proprietary RNA technology and delivery systems, and our internal development programmes into commercial drug products. These elements position us as a leader in our field, focused on bringing RNA therapeutics to patients.
Silence also has the know-how and the patented technology to help RNA therapeutics companies develop specific and stable RNAi molecules and has already established equitable relationships with industry partners and academic collaborations.
This breadth of expertise is reinforced by our own internally developed drug development programmes, as well as our pre-clinical pipeline.
Recent successful fundraisings have allowed us to diversify our pre-clinical pipeline to evaluate more potential uses for our technology at any one time. We are investing in our pre-clinical engine and through our dedicated translational medicine team, will steadily bring more targets through for development in the clinic.
Silence Therapeutics is a leading RNA technology company.
We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. Our technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo.
This allows the development of therapeutics for diseases with high unmet clinical need. Silence’s technology is currently in the clinic in a Phase 2a pancreatic cancer trial.
RNA (ribonucleic acid) is one of the two types of nucleic acids found in all cells – the other being DNA (deoxyribonucleic acid). RNA is the messenger that takes a copy of the genetic information stored in DNA in a cell’s nucleus and translates it into instructions for the manufacture of proteins in that cell.
RNA interference (RNAi) is a method of regulating or ‘silencing’ gene expression. It is a naturally occurring phenomenon which can be used to selectively supress the genes which cause some diseases. Genes are the blueprints for proteins, the building blocks of life, and this technology can selectively silence potentially any gene in the genome, preventing the overexpression of that gene and reducing the production of disease-causing proteins.
The ability to specifically target these proteins could open the door to types of therapeutics that current treatments such as small molecules and antibodies cannot address.
Our patented RNAi platform is known as AtuRNAi®. It is based on specific, proprietary short interfering RNA (siRNA) modules, stabilisation technology and exclusive tailored features.
siRNA requires delivery systems in order to enable it to enter into target cells within the body. Silence has its own delivery systems focused on a variety of organs:
- AtuPLEX® targets the endothelial cells of the vascular system
- DACC targets the endothelial cells of the lung
- HepaPLEX targets the hepatocyte cells of the liver and the liver’s vascular system
We use our technology in our own pre-clinical research and clinical trial programmes, resulting in a promising pipeline. We also license our technology to other drug development and pharmaceutical companies.
Lead programme: Atu027
Atu027 is a drug that uses our AtuPLEX® and AtuRNAi® technologies to target the expression of the protein PKN3 which is believed to be a key factor in cancer progression and metastasis. Atu027 is currently being tested in a Phase 2a trial in subjects with advanced solid tumours. The primary aim of this trial is to evaluate the safety of the drug.
Rather than decreasing gene function, mRNA delivery is an exciting new method of introducing messenger RNA activity into the cell and stimulating it to produce a target protein, in conditions where this is of therapeutic interest, including genetic deficiencies. This way improved gene expression is achieved without having to make permanent changes to the genome, thus avoiding safety concerns.
We have already demonstrated our ability to deliver functional mRNA in vivo and are actively exploring new opportunities in this space.
More detail on our RNAi Platform or our Delivery Platform
Find out more about our Pipeline
Find out more about our Intellectual Property
Find out more about RNA Interference
Dr Stephen Parker - Chairman
Stephen has extensive board level expertise, and is currently a Director of sp2 Consulting Limited. Previously a partner at Celtic Pharma, he was also Chief Financial Officer of Oxford GlycoSciences. He brings sector corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings, Warburg and Apax Partners.
Ali Mortazavi - Chief Executive
Ali joined Silence in 2012, leading its refinancing and refocusing the business. He has extensive expertise in UK small companies, particularly in biotechnology investment and ventures. Ali has over 17 years’ experience in finance having co-founded Evolution Securities in 2001, heading up the Group’s principal trading division.
David Ellam - Chief Financial Officer
David Ellam joined Silence Therapeutics as Chief Financial Officer (CFO) and a director from 18 July 2016.
He has previously occupied several senior finance roles within both US & UK publicly owned life science companies, most recently as Senior EUMEA Finance Director at BioMarin Pharmaceuticals Inc. from 2010 to 2016, as CFO of Plethora Solutions Plc (2008-2009) and as Group Financial Controller at Ark Therapeutics Plc (2001-2008).
He is a Chartered Accountant.
Timothy Freeborn - Managing Director - Silence Therapeutics
Timothy also joined Silence in 2012, bringing over 20 years’ experience in finance. After qualifying as a chartered accountant and specialising in corporate tax, he spent twelve years as a financial journalist on a national newspaper and eight years as a stockbroking analyst, covering electronics, chemicals and alternative energy.
Since 1 July 2016 Timothy has been full time in Berlin.
Corporate Headquarters UK
1 Lyric Square
London W6 0NB
Tel: +44 (0) 203 700 9711
Nominated adviser and joint broker:
Canaccord Genuity Limited
88 Wood Street
+44 (0)20 7523 8321
Peel Hunt LLP
120 London Wall
+44 (0)20 7418 8900
Covington & Burling LLP
+44 (0)20 7067 2000
+44 (0)1223 460055
Capita IRG plc
+44 (0)871 664 0300